Joint Clinical Trials Office

You are here

Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma

Clinical Trial Details

This clinical trial is for men and women age 18 and older with esophagogastric adenocarcinoma to check the safety, efficacy and tolerability of Telomelysin (OBP-301) in combination with Pembrolizumab. 

In North America, gastric cancer is the third most common gastrointestinal malignancy and the third most lethal neoplasm overall. The standard primary therapy is surgical resection. 

Despite advances in developing targeted therapies across solid tumor malignancies, progress in cancers of the upper gastrointestinal tract (esophagus and gastric cancers) has been limited. Despite recent advances, the average survival for metastatic disease is approximately 10 months, and more than 80% of patients diagnosed with an esophageal or gastric cancer will ultimately die of their disease. There is a need to find more effective treatment with better survival outcomes. 

OBP-301 stimulates the immune system and may stop cancer cells from growing. The non-clinical and clinical observations suggest that OBP-301 and pembrolizumab combined therapy may produce superior anti-tumor activity compared to one drug alone. 

Key Eligibility: 
  • Open to men and women 18 years and older 
  • Pathologically confirmed with advanced or metastatic gastric or gastroesophageal adenocarcinoma
  • Has received at least 2 lines of systemic therapy for advanced disease
  • Detailed eligibility reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Sabrina Machado, RN

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group